table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 all comers
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment LIFESAVER
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose
tocilizumab TOCOVID BACC Bay Tocilizumab Trial
janus kinase (JAK) inhibitor
baricitinib RECOVERY
leflunomide Wang

25 studies excluded by filtering options 1

4930 Huijie Bian, 2020 2313excludednot a RCThigh risk of bias
5317 Lu, 2020 1223not a RCThigh risk of bias
5319 Wu, 2020 1133not a RCThigh risk of bias
5453 Raef, 2020 1134not a RCThigh risk of bias
5454 Jianfeng, 2020 1133not a RCThigh risk of bias
5455 Tomasz, 2020 1204not a RCThigh risk of bias
5456 Fernández Cruz, 2020 1133not a RCThigh risk of bias
5476 Yuan, 2020 0130selection pending
5484 Salton (Methylprednisolone), 2020 0134selection pending
5485 openSafely, 2020 0130selection pending
5510 Malgorzata, 2020 1134not a RCThigh risk of bias
5552 Rahman, 2020 0130selection pending
5568 Zhang, 2020 0130selection pending
5603 Albani, 2020 0130selection pending
5612 Bernaola, 2020 2130excludednot a RCTrisk of bias not avaialble
5614 Monreal, 2020 0130selection pending
5615 Nelson (Methylprednisolone), 2020 0130selection pending
5639 Li (Methylprednisolone, Shanghai cohort), 2020 0130selection pending
5796 SAM-COVID-19, 2020 0130selection pending
5840 Majmundar, 2020 0130selection pending
5939 Li (Methylprednisolone, Validation cohort), 2020 0130selection pending
5952 Rodriguez-Bano (intermediate-high dose CS), 2020 0130selection pending
5953 Rodriguez-Bano (CS pulse dose), 2020 0130selection pending
6036 Esba, 2020 0100selection pending
6048 Wu, 2020 0110selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons